Abstract
Background Emergency Departments (EDs) can serve as surveillance sites for infectious diseases. Our purpose was to determine the burden of SARS-CoV-2 infection and prevalence of vaccination against COVID-19 among patients attending an urban ED in Baltimore City.
Methods Using 1914 samples of known exposure status, we developed an algorithm to differentiate previously infected, vaccinated, and unexposed individuals using a combination of antibody assays. We applied this testing algorithm to 4360 samples ED patients obtained in the springs of 2020 and 2021. Using multinomial logistic regression, we determined factors associated with infection and vaccination.
Results For the algorithm, sensitivity and specificity for identifying vaccinated individuals was 100% and 99%, respectively, and 84% and 100% for naturally infected individuals. Among the ED subjects, seroprevalence to SARS-CoV-2 increased from 2% to 24% between April 2020 and March 2021. Vaccination prevalence rose to 11% by mid-March 2021. Marked differences in burden of disease and vaccination coverage were seen by sex, race, and ethnicity. Hispanic patients, though 7% of the study population, had the highest relative burden of disease (17% of total infections) but similar vaccination rates. Women and White individuals were more likely to be vaccinated than men or Black individuals (adjusted odds ratios [aOR] 1.35 [95% CI: 1.02, 1.80] and aOR 2.26 [95% CI: 1.67, 3.07], respectively).
Conclusions Individuals previously infected with SARS-CoV-2 can be differentiated from vaccinated individuals using a serologic testing algorithm. SARS-CoV-2 exposure and vaccination uptake frequencies reflect gender, race and ethnic health disparities in this urban context.
Summary Using an antibody testing algorithm, we distinguished between immune responses from SARS-CoV-2-infected and vaccinated individuals. When applied to blood samples from an emergency department in Baltimore, disparities in disease burden and vaccine uptake by sex, race, and ethnicity were identified.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Other support was provided by extramural support from NIAID [R01AI120938, R01AI120938S1, and R01AI128779, K01AI100681, UM1‐AI068613]; the NIH Center of Excellence in Influenza Research and Surveillance [HHSN272201400007C]; and the National Heart Lung and Blood Institute [K23HL151826].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Johns Hopkins University School of Medicine Institutional Review Board of the Johns Hopkins University School of Medicine gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Evan J Beck ebeck14{at}jhmi.edu
Yu-Hsiang Hsieh yhiesh1{at}jhmi.edu
Reinaldo E Fernandez rferna25{at}jhmi.edu
Gaby Dashler ggladfe1{at}jhmi.edu
Emily Egbert eegbert1{at}jh.edu
Shawn A Truelove shawntruelove{at}jhmi.edu
Caroline Garliss Caroline.Garliss{at}jhmi.edu
Richard Wang rwang93{at}jhmi.edu
Evan M. Bloch ebloch2{at}jhmi.edu
Ruchee Shrestha ruchee{at}jhu.edu
Joel Blankson jblanks{at}jhmi.edu
Andrea L. Cox acox6{at}jhmi.edu
Yukari C Manabe ymanabe{at}jhmi.edu
Thomas Kickler ttickler{at}jhmi.edu
Richard E Rothman rrothma1{at}jhmi.edu
Andrew R Redd aredd2{at}jhmi.edu
Aaron AR Tobian atobian1{at}jhmi.edu
Aaron Milstone amilsto1{at}jhmi.edu
Thomas C Quinn tquinn2{at}jhmi.edu
Oliver Laeyendecker olaeyen1{at}jhmi.edu
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
24
Blogs/Media
Author Videos